Immunotherapy with Immunocytokines and PD-1 Blockade Enhances the Anticancer Activity of Small Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX.
|
| Abstract |
Small molecule-drug conjugates (SMDCs) represent an alternative to conventional antitumor chemotherapeutic agents, with the potential to improve the therapeutic window of cytotoxic payloads through active delivery at the site of the disease. In this article, we describe novel combination therapies consisting of anti-carbonic anhydrase IX SMDCs combined with different immunomodulatory products. The therapeutic effect of the SMDCs was potentiated by combination with PD-1 blockade and with tumor-homing antibody-cytokine fusions in mouse models of renal cell carcinoma and colorectal cancer. The combination with L19-IL12, a fusion protein specific to the alternatively spliced EDB domain of fibronectin containing the murine IL12 moiety, was also active against large established tumors. Analysis of the microscopic structures of healthy organs performed 3 months after tumor eradication confirmed absence of pathologic abnormalities in the healthy kidney, liver, lung, stomach, and intestine. Our findings may be of clinical significance as they provide motivation for the development of combinations based on SMDCs and immunotherapy for the treatment of renal cell carcinoma and hypoxic tumors.
|
|---|---|
| Authors | Jacopo Millul, Christiane Krudewig, Aureliano Zana, Sheila Dakhel Plaza, Emanuele Puca, Alessandra Villa, Dario Neri, Samuele Cazzamalli |
| Journal | Molecular cancer therapeutics (Mol Cancer Ther) Vol. 20 Issue 3 Pg. 512-522 (03 2021) ISSN: 1538-8514 [Electronic] United States |
| PMID | 33443104 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Copyright | ©2020 American Association for Cancer Research. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!